How should I manage an 84‑year‑old patient with impaired renal function (estimated glomerular filtration rate 42 mL/min/1.73 m², stage 3 chronic kidney disease)?

Management of an 84-Year-Old with Stage 3a CKD (GFR 42)

This patient has Stage 3a chronic kidney disease and requires comprehensive management focused on slowing progression, reducing cardiovascular risk, and monitoring for complications—even at age 84, this GFR level is associated with increased risks of kidney failure, cardiovascular disease, and death that warrant active intervention. 1

Initial Assessment and Classification

Your patient's GFR of 42 mL/min/1.73 m² places them in Stage 3a CKD (GFR 30-59 mL/min/1.73 m²), which can be diagnosed based on GFR alone without requiring additional markers of kidney damage. 2 However, you must:

• Measure urine albumin-to-creatinine ratio (ACR) immediately, as this determines treatment intensity and is essential for risk stratification. 3, 4
• Confirm chronicity by documenting that kidney dysfunction has persisted for ≥3 months. 2, 5
• Assess for diabetes, hypertension, and cardiovascular disease, as these drive both CKD etiology and management priorities. 5, 6

Pharmacologic Nephroprotection

SGLT2 Inhibitors (First-Line Therapy)

Start an SGLT2 inhibitor regardless of diabetes status if any of the following apply: 3

• ACR ≥200 mg/g (≥20 mg/mmol) — Class 1A recommendation
• Heart failure present — Class 1A recommendation, irrespective of albuminuria level
• ACR <200 mg/g without heart failure — Class 2B recommendation (weaker but still suggested)

The SGLT2i should be continued even if GFR subsequently falls below 20 mL/min/1.73 m², unless intolerance or dialysis initiation occurs. 3 Withhold temporarily during prolonged fasting, surgery, or critical illness due to ketosis risk. 3 The initial reversible GFR dip after starting SGLT2i is not an indication to stop therapy. 3

RAS Inhibitors (ACE-I or ARB)

Initiate ACE inhibitor or ARB based on albuminuria status: 3

• ACR ≥300 mg/g (A3, severely increased albuminuria) — Class 1B recommendation with or without diabetes
• ACR 30-299 mg/g (A2, moderately increased albuminuria) — Class 1B recommendation if diabetic; Class 2C if non-diabetic
• ACR <30 mg/g (A1) — Consider for specific indications like hypertension or heart failure with reduced ejection fraction 3

Titrate to the maximum approved tolerated dose, as trial benefits were achieved at these doses. 3 Monitor serum creatinine and potassium within 2-4 weeks of initiation or dose increase. 3 Continue therapy unless creatinine rises >30% within 4 weeks, or symptomatic hypotension or uncontrolled hyperkalemia develops. 3 Crucially, continue ACE-I/ARB even when GFR falls below 30 mL/min/1.73 m² unless GFR <15 with uremic symptoms. 3

Nonsteroidal Mineralocorticoid Receptor Antagonist

If the patient has type 2 diabetes, ACR >30 mg/g despite maximum tolerated RAS inhibitor, normal potassium, and GFR >25 mL/min/1.73 m², consider adding finerenone (Class 2A recommendation). 3 This can be combined with both RASi and SGLT2i. 3 Monitor potassium closely: initiate only if K+ ≤4.8 mmol/L. 3

Blood Pressure Management

Target standardized office systolic BP <140 mmHg (or lower if tolerated without symptomatic hypotension). 3 The 2024 KDIGO guidelines emphasize protocol-driven BP measurement. 3 Optimal BP control reduces cardiovascular events, which are 5-10 times more likely to cause death than progression to kidney failure in CKD patients. 6

Lipid Management

Initiate statin therapy for cardiovascular risk reduction, as cardiovascular disease is the leading cause of death in CKD. 5, 6 Target total cholesterol <4.5 mmol/L and LDL <2.5 mmol/L based on evidence showing improved outcomes with primary care CKD management programs. 7

Monitoring for CKD Complications

At GFR 42, routine screening for typical CRF complications (anemia, metabolic acidosis, mineral bone disease) is not yet indicated, as these manifestations are uncommon until GFR falls below 30 mL/min/1.73 m². 8, 9 However, monitor:

• Serum creatinine and GFR every 6-12 months to track progression 5
• Potassium regularly, especially after initiating RASi or MRA 3
• Albuminuria annually to assess treatment response 3

Begin screening for anemia, hyperphosphatemia, vitamin D deficiency, and metabolic acidosis when GFR approaches 30 mL/min/1.73 m². 5, 9

Nephrotoxin Avoidance and Medication Adjustment

• Avoid NSAIDs and other nephrotoxic agents 5
• Adjust dosing of renally cleared medications (many antibiotics, oral hypoglycemics, etc.) 5
• Review all medications for appropriate GFR-based dosing

Nephrology Referral Criteria

Do not refer to nephrology at this stage unless: 5

• GFR declines rapidly (>5 mL/min/1.73 m² per year)
• ACR ≥300 mg/g develops
• GFR falls below 30 mL/min/1.73 m²
• Uncontrolled hypertension or hyperkalemia despite treatment
• Unexplained hematuria or other concerning features

Age-Specific Considerations

Despite the patient's age of 84, this GFR level carries significant prognostic implications. Recent data confirm that GFR 45-59 mL/min/1.73 m² in older adults (≥75 years) is independently associated with increased risks of kidney failure (HR 3.05), cardiovascular disease (HR 1.10), and all-cause mortality (HR 1.17), even without proteinuria. 1 This justifies active management rather than attributing reduced GFR solely to "normal aging."

Common Pitfalls

• Do not withhold SGLT2i or RASi based on age alone—the evidence supports use in older adults 1
• Do not stop RASi for modest creatinine rises (<30%) or initial GFR dips with SGLT2i 3
• Do not screen for anemia/bone disease prematurely at this GFR level 8, 9
• Manage hyperkalemia medically (dietary modification, diuretics, potassium binders) rather than immediately stopping RASi 3